Introduction {#Sec1}
============

The head (including the scalp and face) and neck are the body areas most commonly affected by psoriasis, and, in many cases, the most difficult areas to treat \[[@CR1]--[@CR3]\]. Scalp psoriasis is estimated to affect between 40% and 90% of individuals with psoriasis, and facial psoriasis has been reported by 17--29% of adults with psoriasis \[[@CR2], [@CR4]\]. In addition to physical symptoms of itching, pain, lesion cracking, and bleeding that may cause discomfort and reduced quality of life, individuals with extensive and highly visible psoriasis affecting areas such as the head and neck can experience higher psychological burdens \[[@CR2], [@CR5], [@CR6]\]. Symptoms of psoriasis can cause patients to face social stigmatization that results in embarrassment, shame, and stress \[[@CR7]\]. Visible psoriasis can also negatively affect work or school attendance and performance, reduce self-confidence, and interfere with daily routines \[[@CR2], [@CR8]\].

The disease burden in patients with head and neck psoriasis is substantial. Patients with facial psoriasis have significantly greater whole body Psoriasis Severity Area Index (PASI) scores than patients without facial involvement (15.6 vs. 6.9; *P* \< 0.05) and facial psoriasis is associated with longer disease duration and younger age of onset \[[@CR9], [@CR10]\]. Quality of life is more negatively impacted in women with scalp psoriasis, and many individuals with scalp psoriasis report being inconvenienced by caring for their scalp \[[@CR11], [@CR12]\]. Additionally, scalp psoriasis has been shown to impair physical and psychological health regardless of the severity of psoriasis on other body regions \[[@CR13]\].

Secukinumab is a human monoclonal antibody that selectively binds to and neutralizes interleukin (IL)-17A, a key cytokine in the pathogenesis of psoriasis \[[@CR14]\]. The safety and efficacy of secukinumab has previously been demonstrated in phase 3 studies of patients with moderate-to-severe plaque psoriasis \[[@CR15]--[@CR18]\]. In this report, 52-Week results were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe psoriasis, and efficacy was evaluated for (1) head and neck (HN)PASI subscores and (2) whole body composite PASI scores. Subcomponent PASI results for the trunk, upper limbs, and lower limbs are reported separately in this publication by Menter et al. \[[@CR19]\].

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

Data were pooled from four randomized, double-blind, placebo-controlled, parallel-group phase 3 trials \[efficacy of response and safety of two fixed secukinumab regimens in psoriasis (ERASURE, ClinicalTrials.gov identifier, NCT01365455), full year investigative examination of secukinumab vs. etanercept using two dosing regimens to determine efficacy in psoriasis (FIXTURE, ClinicalTrials.gov identifier, NCT01358578), first study of secukinumab in pre-filled syringes in subjects with chronic plaque-type psoriasis (FEATURE, ClinicalTrials.gov identifier, NCT01555125), and judging the efficacy of secukinumab in patients with psoriasis using autoinjector (JUNCTURE, ClinicalTrials.gov identifier, NCT01636687)\]. The design of these trials has been previously reported in detail \[[@CR15]--[@CR17]\]. Briefly, secukinumab or placebo was administered at Baseline, Weeks 1, 2 and 3, and then every 4 weeks from Week 4 to 48. At Week 12, patients receiving placebo were randomized to secukinumab. Secukinumab was administered by subcutaneous injection; in ERASURE and FIXTURE the lyophilisate in vial formulation was used, in FEATURE a prefilled syringe was used, and in JUNCTURE an autoinjector was used.

Study Population {#Sec4}
----------------

Male and female patients (≥18 years of age) with moderate-to-severe plaque psoriasis of ≥6 months' duration that was poorly controlled by topical treatments, phototherapy, and/or previous systemic therapy were considered eligible for the study population. Moderate-to-severe plaque psoriasis was defined as Baseline PASI score ≥12, Investigator's Global Assessment modified 2011 (IGA mod 2011) \[[@CR20]\] score ≥3, and total body surface area (BSA) affected ≥10%. Exclusion criteria included active, ongoing inflammatory diseases; active, ongoing, chronic or recurrent infectious disease, or evidence of active tuberculosis infection; or underlying condition significantly immunocompromising the patient and/or placing the patient at unacceptable risk for receiving an immunomodulatory therapy (e.g., lymphoproliferative disease, malignancy, history of malignancy within the past 5 years; past medical history of HIV, hepatitis B, or hepatitis C). To be included in the head and neck subanalysis, patients had to have a PASI score ≥12 for the head and neck region and have psoriasis covering ≥10% of the BSA of the head and neck region. Composite PASI scores are calculated as a weighted average of PASI scores for the head and neck, upper limbs, trunk, and lower limbs using multipliers of 0.1, 0.2, 0.3, and 0.4, respectively, to account for the relative percentage of total BSA these regions make up. Scores for each body region are calculated as the affected area (A) score multiplied by the sum of erythema (E), induration (I), and desquamation (D) scores for that body region.

Efficacy and Safety Assessments {#Sec5}
-------------------------------

Co-primary efficacy variables in all four trials were PASI 75 response rates and IGA mod 2011 0/1 response rates at Week 12. PASI 90 response rate at Week 12 was a key secondary endpoint in all trials. PASI 100 response rates at Week 12 and achievement of dermatology life quality index (DLQI) \[[@CR21]\] scores of 0/1, representing little or no effect of psoriasis on patient quality of life, were also measured. Safety and tolerability assessments included vital signs, clinical laboratory variables, electrocardiograms, and adverse event (AE) monitoring. Week 52 safety data were pooled from all 4 studies.

Statistical Analysis {#Sec6}
--------------------

Data from ERASURE, FIXTURE, FEATURE, and JUNCTURE were pooled to assess long-term efficacy through Week 52. Missing values were imputed by multiple imputation (MI), in which missing data are replaced by values derived from large data sets of possible values. The SAS (version 9.3, SAS Institute, Cary, NC, USA) MI procedure was used to generate data sets for 500 imputations. Results are presented by MI because this method more accurately reflects response rates observed in a clinical setting than the more conservative non-responder imputation method, which underestimates PASI responses \[[@CR22]\]. Efficacy results are presented for the full analysis set of patients, which is defined as all patients to whom study treatment had been assigned. Safety results are presented for the safety set of patients, which is defined as all patients who took at least one dose of study treatment during the treatment period and who had at least one Post-Baseline safety assessment. This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.

Results {#Sec7}
=======

Patient Demographics {#Sec8}
--------------------

Treatment groups were well balanced for demographic and Baseline disease characteristics in the overall study population (Table [1](#Tab1){ref-type="table"}). Baseline disease characteristics were representative of the target population with moderate-to-severe plaque psoriasis. The mean age of patients at Baseline was 45 years, and approximately 70% of participants were White men. Patients had a mean body weight of approximately 86 kg and a mean body mass index of approximately 29 kg/m^2^. Disease severity was comparable across treatment groups. Mean PASI scores at Baseline were 22.7 for patients receiving secukinumab 300 mg, 22.8 for patients receiving secukinumab 150 mg, and 22.5 for patients receiving placebo.Table 1Patient demographics and Baseline disease characteristics (overall population)Secukinumab 300 mg (*n* = 691)Secukinumab 150 mg (*n* = 692)Placebo (*n* = 692)Gender (male), *n* (%)477 (69.0)485 (70.1)484 (69.9)Age (years), mean (SD)44.9 (13.3)45.1 (13.4)44.7 (12.8) Range18--8318--8318--82Race, *n* (%) White505 (73.1)499 (72.1)509 (73.6) Asian129 (18.7)129 (18.6)121 (17.5) Black9 (1.3)13 (1.9)13 (1.9) Other48 (6.9)51 (7.4)49 (7.1)Height (cm), mean (SD)^a^171.2 (9.6)171.3 (10.2)171.6 (10.2) Range145.0--198.5145.0--197.0141.0--200.7Weight (kg), mean (SD)86.6 (23.2)86.6 (23.2)86.0 (22.6) Range45.0--219.143.1--215.042.0--191.9BMI (kg/m^2^), mean (SD)^a^29.4 (6.9)29.4 (7.0)29.1 (6.9) Range17.4--67.416.5--79.716.2--71.2PASI score, mean (SD)22.7 (9.4)22.8 (10.0)22.5 (9.7) Range11.2--72.012.0--69.610.6--72.0IGA modified 2011 score, *n* (%) 3 (Moderate disease)436 (63.1)439 (63.4)424 (61.3) 4 (Severe disease)255 (36.9)253 (36.6)268 (38.7)Time since first psoriasis diagnosis (y), mean (SD)17.0 (12.0)17.9 (12.5)17.5 (12.2) Range0.5--61.50.5--69.00.5--68.1Previous exposure to systemic psoriasis therapy^b^ (yes), *n* (%)438 (63.4)447 (64.6)420 (60.7)Previous exposure to biologic systemic psoriasis therapy^b^ (yes), *n* (%)146 (21.1)161 (23.3)147 (21.2)Previous exposure to non-biologic systemic psoriasis therapy^b^ (yes), *n* (%)373 (54.0)393 (56.8)363 (52.5)Results are for the full analysis set of patients*BMI* body mass index, *BSA* body surface area, *IGA* investigator's global assessment, *PASI* psoriasis area and severity index, *SD* standard deviation^a^ *n* = 688 for secukinumab 300 mg, *n* = 692 for secukinumab 150 mg^b^ *n* = 690 for secukinumab 300 mg

Head and Neck Efficacy {#Sec9}
----------------------

Treatment with secukinumab 300 mg and secukinumab 150 mg resulted in rapid and sustained skin clearance on the head and neck. For secukinumab 300 mg, initial HNPASI 75, 90, and 100 response rates were maintained to Week 52. At Week 16, 82.4% and 72.2% of patients receiving secukinumab 300 mg had HNPASI 90 and HNPASI 100 responses, respectively. At Week 52, HNPASI 90 and HNPASI 100 response rates were achieved by 76.0% and 68.7%, respectively, of patients receiving secukinumab 300 mg. With secukinumab 150 mg, HNPASI 90 and 100 response rates were achieved by 69.9% and 57.7% of patients at Week 16, respectively and by 61.4% and 53.1% of patients at Week 52, respectively (Fig. [1](#Fig1){ref-type="fig"}). A 50% reduction in mean HNPASI score occurred after 2.0 weeks (95% confidence interval \[CI\] 1.9, 2.2) with secukinumab 300 mg and after 2.7 weeks (95% CI 2.6, 2.9) with secukinumab 150 mg (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Efficacy of secukinumab on the head and neck over time. Missing values were imputed by multiple imputation. Clinical response rates for **a** HNPASI 75, **b** HNPASI 90, and **c** HNPASI 100 from Baseline to Week 52. *n* represents the number of evaluable subjects. HNPASI 75/90/100, 75%/90%/100% improvement from Baseline head and neck psoriasis area and severity index scores Fig. 2Percent change in mean HNPASI score over time. A repeated-measure, mixed-effects model was used to analyze the mean percent change from Baseline in PASI score. The median time to a 50% reduction in mean HNPASI score was estimated from parametric bootstrap samples with the use of linear interpolation between time points. *CI* confidence interval, *HNPASI* head and neck psoriasis area severity index

Whole Body Efficacy {#Sec10}
-------------------

Pooled efficacy responses through Week 52 from these four phase 3 trials are presented in Fig. [3](#Fig3){ref-type="fig"}. In the overall pooled study population, secukinumab provided rapid skin clearance with responses being observed as early as Week 1. Initial responses were maintained to Week 52 and the greatest benefit was observed with secukinumab 300 mg. At Week 52, PASI 90 and PASI 100 were achieved by 68.1% and 40.8% of patients receiving secukinumab 300 mg, respectively, and by 47.6% and 24.3% of patients receiving secukinumab 150 mg, respectively.Fig. 3Efficacy of secukinumab on the whole body over time. Missing values were imputed by multiple imputation. Clinical response rates for **a** PASI 75, **b** PASI 90, and **c** PASI 100 from Baseline to Week 52. PASI 75/90/100, 75%/90%/100% improvement from Baseline psoriasis area and severity index scores

Treatment with secukinumab also showed rapid and significant improvement in quality of life as measured by DLQI. At Week 12, DLQI scores of 0 or 1 were achieved by 58.8% of patients receiving secukinumab 300 mg and 50.1% of patients receiving secukinumab 150 mg. Improvements in DLQI continued to Week 52 with DLQI scores of 0 or 1 being achieved by 67.9% and 53.7% of patients receiving secukinumab 300 mg and secukinumab 150 mg, respectively. Mean decreases (improvements) in DLQI from Baseline to Week 52 were −11.0 with secukinumab 300 mg and −9.2 with secukinumab 150 mg, and these responses surpassed the ≥5-point reduction in DLQI required for a minimal clinically important difference in patients with psoriasis that are receiving biologic therapy \[[@CR23]\].

Safety {#Sec11}
------

Secukinumab demonstrated a favorable safety profile in the overall pooled study population, and the rates of AEs were similar between the 300 and 150 mg doses (Table [2](#Tab2){ref-type="table"}). Through Week 52, AEs were reported in 83.3% of patients receiving secukinumab 300 mg and in 81.2% of patients receiving secukinumab 150 mg. The most common AEs for both secukinumab doses were nasopharyngitis (23.7--24.9%), headache (9.4--11.4%), diarrhea (6.5--7.8%), and upper respiratory tract infection (7.7--9.2%). Serious AEs were reported in 7.0% of patients receiving secukinumab 300 mg and in 6.9% of patients receiving secukinumab 150 mg. Discontinuation of secukinumab due to AEs occurred in 3.0% of patients receiving secukinumab 300 mg and in 3.6% of patients receiving secukinumab 150 mg.Table 2Summary of adverse eventsPreferred term, *n* (%)52 Weeks12 WeeksSecukinumab 300 mg (*n* = 690)Secukinumab 150 mg (*n* = 692)Placebo (*n* = 694)Discontinuation due to adverse event21 (3.0)25 (3.6)9 (1.3)Any serious adverse event48 (7.0)48 (6.9)12 (1.7)Any adverse event575 (83.3)562 (81.2)340 (49.0)Most common adverse events (\>5%) Nasopharyngitis172 (24.9)164 (23.7)60 (8.6) Headache79 (11.4)65 (9.4)36 (5.2) Diarrhea54 (7.8)45 (6.5)10 (1.4) Upper respiratory tract infection53 (7.7)64 (9.2)5 (0.7) Cough45 (6.5)21 (3.0)9 (1.3) Back pain37 (5.4)30 (4.3)10 (1.4) Hypertension35 (5.1)37 (5.3)12 (1.7) Arthralgia34 (4.9)38 (5.5)17 (2.4)Results are for the safety set of patients. Safety results are only presented to Week 12 for placebo because at Week 12, patients receiving placebo were randomized to secukinumab

Discussion {#Sec12}
==========

The efficacy of secukinumab 300 mg and secukinumab 150 mg was previously demonstrated to be superior to placebo (in ERASURE, FIXTURE, FEATURE, and JUNCTURE) and etanercept (in FIXTURE) at Week 12 \[[@CR15]--[@CR17]\]. Results from this pooled analysis of four phase 3 trials show that secukinumab is effective for the treatment of moderate-to-severe psoriasis affecting the head and neck, and the whole body. Secukinumab therapy resulted in rapid improvement of psoriasis on the head and neck. Improvements were observed as early as Week 1 at which point secukinumab 300 mg provided an approximate 25% reduction in mean HNPASI score from Baseline. Disease clearance continued to increase on the head and neck after the first Week, and patients experienced a 50% reduction in mean HNPASI score after 2.0 weeks of treatment with secukinumab 300 mg. Improvement in psoriasis affecting the head and neck were maintained through Week 52, with the greatest benefit seen in patients receiving secukinumab 300 mg (Fig. [1](#Fig1){ref-type="fig"}).

The efficacy and safety of secukinumab was consistent across all four phase 3 trials that were pooled for this analysis. Results from this study are also consistent with findings from other studies that evaluated the efficacy of biologic agents by body region \[[@CR24]--[@CR26]\]. In these studies, along with the findings reported here, head and neck plaque psoriasis generally responded favorably, rapidly, and significantly to biologic treatment. Conversely, psoriasis on the head and neck does not typically respond well to conventional systemic therapies, and topical therapies can be burdensome to apply resulting in low adherence \[[@CR26], [@CR27]\]. This study was limited by the inability to differentiate between affected areas of the head and neck (e.g., scalp vs face psoriasis) because PASI does not allow for differentiation of specific regions of the head and neck. A study is currently ongoing that will evaluate the efficacy of secukinumab on scalp psoriasis, and results from this trial will provide further data on the treatment of this difficult to manage area \[[@CR28]\]. Additionally, there was no control group after Week 12.

Results of this pooled analysis demonstrate that secukinumab is an effective and well-tolerated treatment for plaque psoriasis of the head and neck. The majority of the patients treated with secukinumab 300 mg achieved almost clear or clear skin as indicated by high HNPASI 90 and HNPASI 100 response rates. Secukinumab also provided robust overall efficacy. At Week 12, PASI 75 response rates were similar between the head and neck region and the whole body. A larger proportion of patients receiving secukinumab 300 mg achieved HNPASI 90 and HNPASI 100 (73.3% and 61.1%, respectively) response rates at Week 12 than achieved composite PASI 90 and PASI 100 (59.6% and 29.0%, respectively) response rates over the same time period. These findings indicate that patients achieve complete or almost complete clearance of psoriasis on the head and neck at a quicker rate than on the whole body following treatment with secukinumab. Likewise, at Week 52, HNPASI response rates were numerically greater than composite PASI response rates. With secukinumab 300 mg, HNPASI 90 and HNPASI 100 responses were achieved by 76.0% and 68.7% of patients, respectively, compared with composite PASI 90 and PASI 100 response rates of 68.1% and 40.8%, respectively. It is important to note that achievement of a PASI 100 response for a particular body region is easier than achievement of the same response for the whole body because full clearance across all body regions is not required. The rapid and sustained clearance of psoriasis from the head and neck with secukinumab may provide patients with a meaningful improvement in areas of the body that are associated with a large psychosocial burden.

In the overall pooled analysis population, disease clearance was associated with improvement in quality of life for patients receiving secukinumab. In ERASURE and FIXTURE, findings from the Psoriasis Symptom Diary© indicate that improvements in PASI response rates are paralleled by significant reductions in patient-reported symptoms of itching, pain, and scaling \[[@CR29]\]. Additionally, improvements in DLQI at Week 52 with secukinumab were sufficient to meet the definition of a clinically important difference in health-related quality of life for patients with psoriasis who are receiving biologic therapy \[[@CR23]\]. The importance of such improvement in DLQI should be highlighted because it is an indicator of patient satisfaction with therapy and likely leads to stronger adherence and better clinical outcomes.

Conclusion {#Sec13}
==========

Pooled results of four phase 3 studies of secukinumab showed robust and sustained efficacy in treating psoriasis affecting both the head and neck and the whole body.
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